CSPC Pharmaceutical Group’s Stock Price Plummets to 4.85 HKD, Marking a Sharp 6.37% Decline

CSPC Pharmaceutical Group (1093)

4.85 HKD -0.33 (-6.37%) Volume: 200.54M

CSPC Pharmaceutical Group’s stock price stands at 4.85 HKD, marking a -6.37% change this trading session amidst a trading volume of 200.54M, yet manages a positive +1.46% change YTD, spotlighting the resilience of 1093’s stock performance.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group is experiencing stock price movements following key events in the company. Recently, CSPC Innovation reported a significant financial decline in 2024, which may have impacted investor sentiment. Additionally, the company has scheduled a board meeting for its annual results, adding to the anticipation surrounding CSPC Pharmaceutical Group. With market caps below US$8B, the pharmaceutical group is closely watched by investors looking for potential growth opportunities in the Asian market.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group has a positive long-term outlook. With high scores in Dividend and Value, the company is considered a strong performer in terms of providing returns to investors and being undervalued in the market. Additionally, its scores in Growth and Resilience indicate a solid foundation for future expansion and the ability to withstand market challenges. However, the company’s lower score in Momentum suggests that it may not be experiencing significant short-term price movements.

CSPC Pharmaceutical Group Limited is a pharmaceutical company that focuses on manufacturing and selling a variety of pharmaceutical products, including vitamin C, antibiotics, and generic drugs. In addition to its current product offerings, the company is also involved in the development of innovative drugs and antibiotics. With strong scores in Dividend, Value, Growth, and Resilience, CSPC Pharmaceutical Group is positioned well for long-term success in the pharmaceutical industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma